Journal of Clinical Oncology, Vol 15, 2818-2825, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study

R Glaser, K Rass, S Seiter, A Hauschild, E Christophers and W Tilgen
Department of Dermatology, Christian-Albrechts-University Kiel, Germany.

PURPOSE: Recently, the reverse-transcription polymerase chain reaction (RT-PCR) of tyrosinase messenger RNA (mRNA) was reported to be a useful tool for the detection of circulating tumor cells in the peripheral blood of melanoma patients. Our aim was to evaluate critically the diagnostic value of this marker by investigating a significant number of patients in different stages of the disease in a two-center study. PATIENTS AND METHODS: Different techniques of blood collection, RNA isolation, and RT-PCR were compared, and the detectability of tyrosinase mRNA was tested using nine different melanoma cell lines. The sensitivity of the method was confirmed by blood spiking experiments and the specificity by restriction enzyme analysis. Subsequently, a total of 153 blood samples from 137 individuals (30 healthy subjects, five basal cell carcinoma, and 102 melanoma patients) were investigated. RESULTS: The detection level of melanoma cells differed between the cell lines tested. However, we could reproducibly detect single melanoma cells by spiking whole blood samples from healthy volunteers. One of 43 patients with primary melanoma (2.3%), zero of 15 patients with regional metastasis (0%), and 12 of 44 patients with advanced disease (27.3%) were found to be RT-PCR positive. All blood samples obtained from controls and patients with basal cell carcinoma were tyrosinose mRNA negative. CONCLUSION: Our data support the recent doubts that the detection of circulating tumor cells in melanoma patients using the tyrosinase mRNA RT-PCR is not sensitive enough to be used either as a melanoma progression marker in early stages of the disease or to monitor therapy in advanced stages of the disease.

This article has been cited by other articles:

				K. Koyanagi, A. J. Bilchik, S. Saha, R. R. Turner, D. Wiese, M. McCarter, P. Shen, L. Deacon, D. Elashoff, and D. S.B. Hoon Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial Clin. Cancer Res., November 15, 2008; 14(22): 7391 - 7396. [Abstract] [Full Text] [PDF]

				S. Mocellin, D. Hoon, A. Ambrosi, D. Nitti, and C. R. Rossi The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis Clin. Cancer Res., August 1, 2006; 12(15): 4605 - 4613. [Abstract] [Full Text] [PDF]

				K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S.B. Hoon Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res., June 15, 2006; 66(12): 6111 - 6117. [Abstract] [Full Text] [PDF]

				K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, H.-J. Wang, R. M. Elashoff, H. Takeuchi, N. Umetani, et al. Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial J. Clin. Oncol., November 1, 2005; 23(31): 8057 - 8064. [Abstract] [Full Text] [PDF]

				K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico Jr, H.-J. Wang, E. Hseuh, S. J. O'Day, and D. S.B. Hoon Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients Clin. Chem., June 1, 2005; 51(6): 981 - 988. [Abstract] [Full Text] [PDF]

				C. Voit, M. Kron, J. Rademaker, M. Schwurzer-Voit, W. Sterry, L. Weber, C. Ozdemir, T. Proebstle, and U. Keilholz Molecular Staging in Stage II and III Melanoma Patients and Its Effect on Long-Term Survival J. Clin. Oncol., February 20, 2005; 23(6): 1218 - 1227. [Abstract] [Full Text] [PDF]

				R. Wlodzimierz, P. Rutkowski, Z. I. Nowecki, J. Kulik, A. Nasierowska-Guttmejer, and J. A. Siedlecki Detection of Melanoma Cells in the Lymphatic Drainage after Lymph Node Dissection in Melanoma Patients by Using Two-Marker Reverse Transcriptase-Polymerase Chain Reaction Assay Ann. Surg. Oncol., November 1, 2004; 11(11): 988 - 997. [Abstract] [Full Text] [PDF]

				R. S. Faye, S. Aamdal, H. K. Hoifodt, E. Jacobsen, L. Holstad, E. Skovlund, and O. Fodstad Immunomagnetic Detection and Clinical Significance of Micrometastatic Tumor Cells in Malignant Melanoma Patients Clin. Cancer Res., June 15, 2004; 10(12): 4134 - 4139. [Abstract] [Full Text] [PDF]

				M. Partridge, R. Brakenhoff, E. Phillips, K. Ali, R. Francis, R. Hooper, K. Lavery, A. Brown, and J. Langdon Detection of Rare Disseminated Tumor Cells Identifies Head and Neck Cancer Patients at Risk of Treatment Failure Clin. Cancer Res., November 1, 2003; 9(14): 5287 - 5294. [Abstract] [Full Text] [PDF]

				J. Szenajch, B. Jasinski, A. Synowiec, J. Kulik, M. Chomicka, J. Struzyna, Z. Nowecki, P. Rutkowski, W. Ruka, W. Kupsc, et al. Prognostic Value of Multiple Reverse Transcription-PCR Tyrosinase Testing for Circulating Neoplastic Cells in Malignant Melanoma Clin. Chem., September 1, 2003; 49(9): 1450 - 1457. [Abstract] [Full Text] [PDF]

				J. P. Dutcher The Prognostic Role of Detection of Circulating Melanoma Cells in the Blood J. Clin. Oncol., March 1, 2003; 21(5): 757 - 759. [Full Text] [PDF]

				G. Palmieri, P. A. Ascierto, F. Perrone, S. M.R. Satriano, A. Ottaiano, A. Daponte, M. Napolitano, C. Caraco, N. Mozzillo, M. T. Melucci, et al. Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction J. Clin. Oncol., March 1, 2003; 21(5): 767 - 773. [Abstract] [Full Text] [PDF]

				B. Mellado, M. del Carmen Vela, D. Colomer, L. Gutierrez, T. Castel, L. Quinto, M. Fontanillas, N. Reguart, J. M. Domingo-Domenech, C. Montagut, et al. Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon J. Clin. Oncol., October 1, 2002; 20(19): 4032 - 4039. [Abstract] [Full Text] [PDF]

				S. Yokoyama and H. Yamaue Prediction of Distant Metastasis by Using Reverse Transcriptase-Polymerase Chain Reaction for Epithelial and Variant CD44 mRNA in the Peripheral Blood of Patients With Colorectal Cancer Arch Surg, September 1, 2002; 137(9): 1069 - 1073. [Abstract] [Full Text] [PDF]

				U. Reinhold, C. Berkin, A.-K. Bosserhoff, A. Deutschmann, C. Garbe, R. Glaser, R. Hein, G. Krahn, R. U. Peter, G. Rappl, et al. Interlaboratory Evaluation of a New Reverse Transcriptase Polymerase Chain Reaction-Based Enzyme-Linked Immunosorbent Assay for the Detection of Circulating Melanoma Cells: A Multicenter Study of the Dermatologic Cooperative Oncology Group J. Clin. Oncol., March 15, 2001; 19(6): 1723 - 1727. [Abstract] [Full Text] [PDF]

				H. Tsao, U. Nadiminti, A. J. Sober, and M. Bigby A Meta-analysis of Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase mRNA as a Marker for Circulating Tumor Cells in Cutaneous Melanoma Arch Dermatol, March 1, 2001; 137(3): 325 - 330. [Abstract] [Full Text] [PDF]

				E. D. Martenson, L.O. Hansson, B. Nilsson, E. von Schoultz, E. M. Brahme, U. Ringborg, and J. Hansson Serum S-100B Protein as a Prognostic Marker in Malignant Cutaneous Melanoma J. Clin. Oncol., February 1, 2001; 19(3): 824 - 831. [Abstract] [Full Text] [PDF]

				B. S. Sorensen, H. Schmidt, H. von der Maase, P. T. Straten, and E. Nexo Quantification of Melanoma Cell-specific MART-1 mRNA in Peripheral Blood by a Calibrated Competitive Reverse Transcription-PCR Clin. Chem., December 1, 2000; 46(12): 1923 - 1928. [Abstract] [Full Text] [PDF]

				M. Johansson, E. K. Pisa, V. Tormanen, K. Arstrand, and B. Kagedal Quantitative Analysis of Tyrosinase Transcripts in Blood Clin. Chem., July 1, 2000; 46(7): 921 - 927. [Abstract] [Full Text] [PDF]

				D. S. B. Hoon, P. Bostick, C. Kuo, T. Okamoto, H.-J. Wang, R. Elashoff, and D. L. Morton Molecular Markers in Blood as Surrogate Prognostic Indicators of Melanoma Recurrence Cancer Res., April 1, 2000; 60(8): 2253 - 2257. [Abstract] [Full Text]

				M. S. Kopreski, F. A. Benko, L. W. Kwak, and C. D. Gocke Detection of Tumor Messenger RNA in the Serum of Patients with Malignant Melanoma Clin. Cancer Res., August 1, 1999; 5(8): 1961 - 1965. [Abstract] [Full Text] [PDF]

				M. Muhlbauer, N. Langenbach, W. Stolz, R. Hein, M. Landthaler, R. Buettner, and A.-K. Bosserhoff Detection of Melanoma Cells in the Blood of Melanoma Patients by Melanoma-inhibitory Activity (MIA) Reverse Transcription-PCR Clin. Cancer Res., May 1, 1999; 5(5): 1099 - 1105. [Abstract] [Full Text] [PDF]

				G. Palmieri, M. Strazzullo, P. A. Ascierto, S. M.R. Satriano, A. Daponte, and G. Castello Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression J. Clin. Oncol., January 1, 1999; 17(1): 304 - 304. [Abstract] [Full Text] [PDF]